Additionally, its potential in mitigating neurodegenerative processes is evaluated through enzyme inhibition assays, particularly focusing on butyrylcholinesterase (BChE), a key enzyme involved in Alzheimer’s disease (Tuzimski and Petruczynik, 2022; Hajlaoui et al., 2021; Mutlu et al., 2023; Cancela et al., 2020; Indrayanto et al., 2021; Agamah et al., 2020). Here, BCHE is linked to early-onset autosomal dominant Alzheimer disease.